ARTICLE | Clinical News
Maxim reports Phase II data
April 20, 2001 7:00 AM UTC
MAXM said that 72-week data from a completed Phase II study showed 40% of evaluable hepatitis C virus patients treated with Ceplene histamine dihydrochloride plus interferon-alpha (IFN-alpha) achieved...